Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OurofinoBSP:OFSA3 +1.08%72 EV-to-EBIT is 5.59 as of Jul. 16, 2026, which is 51% below its 10-year median of 11.41. GuruFocus rates BSP:OFSA3 with a GF Score™ of 72/100 and a GF Value™ of R$26.83 (Fairly Valued). The stock has 2 warning signs investors should review. Among 687 Drug Manufacturers companies, Ourofino ranks better than 89.08% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ourofino's Enterprise Value for the quarter that ended in Mar. 2026 was R$1,606 Mil.
Ourofino's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$283 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ourofino EV-to-EBIT Related Terms
Ourofino EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Ourofino's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:OFSA3 vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ourofino's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ourofino EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ourofino's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ourofino's EV-to-EBIT falls into.
Ourofino's current Enterprise Value is R$1,582 Mil.
Ourofino's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$283 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ourofino (BSP:OFSA3) has a EV-to-EBIT of 5.59 as of Jul. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ourofino and its competitors. This is 51% below median its historical median of 11.41. According to the industry distribution chart, Ourofino ranks #75 out of 687 companies in the Drug Manufacturers industry, placing it in the top 10.9%.
Is Ourofino's EV-to-EBIT too high?
Ourofino's current EV-to-EBIT of 5.59 is 51% below median its 10-year median of 11.41. The Drug Manufacturers industry median EV-to-EBIT is 15.86. Ourofino's value of 5.59 is 64.8% below this industry median. Based on the distribution chart, Ourofino ranks #75 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ourofino has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ourofino's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ourofino ranks #75 out of 687 companies for EV-to-EBIT. This places Ourofino in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.86. Ourofino's value of 5.59 is 64.8% below this benchmark. While the company's 10-year median is 11.41 vs. the industry median of 15.86, Ourofino has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ourofino's current EV-to-EBIT of 5.59 is 64.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ourofino and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ourofino's current EV-to-EBIT is 5.59, which is 51% below median its own 10-year median of 11.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ourofino stock overvalued right now?
Based on GuruFocus' analysis, Ourofino (BSP:OFSA3) is currently considered Fairly Valued. The stock's GF Value™ is R$26.83, compared to a current price of R$27.09 — trading 1% above its estimated fair value. The current EV-to-EBIT is 5.59, which is 51% below median its 10-year median of 11.41 and 64.8% below the Drug Manufacturers industry median of 15.86. Ourofino's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ourofino (BSP:OFSA3), the current EV-to-EBIT is 5.59 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ourofino (BSP:OFSA3) Overvalued in 2026?
Based on GuruFocus' analysis, Ourofino stock appears to be overvalued.
The current stock price of R$27.09 is trading 1% above its estimated GF Value™ of R$26.83.
GuruFocus considers Ourofino to be Fairly Valued.
Key valuation signals for BSP:OFSA3:
EV-to-EBIT: 5.59 (51% below median its 10-year median of 11.41)
GF Value™: R$26.83 vs. price of R$27.09 (1% above fair value)
Industry Position: 64.8% below the Drug Manufacturers median (#75 of 687)
No single metric tells the full story. See the BSP:OFSA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
72GF Score
Get the complete analysis for BSP:OFSA3
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:OFSA3 has been successfully added to your 
